Pharma Sources Insight April 2021: Towards a Future of Immunotherapy

How to subscribe?

Pharma Sources Insight April 2021 focuses on the following topics:

Brand Story

- Interview Jiangxi Fangzun Chemical: Attentively Help Every Customer Create Better Market Value

PHARMA IN CHINA

- A Glimpse of the Oncology Drug Treatment Market in China

- Immune Drug Combination Therapies for Liver Cancer: Analysis of the Clinical Studies of the Two Approved and Two First-line Drug Combinations

- With Anlotinib Sold over RMB4 Billion in 2020, Which will be the Next Blockbuster of Sino Biopharmaceutical?

- Analysis and Policy Review of Pediatric Drug Market in China

GLOBAL MARKET REVIEW

- Antibody-drug Conjugates – Understanding the Trojan Horses

- Towards a Healthier Old Age

Industry Insight

- Industrial Adoption of Continuous Pharmaceutical Manufacturing

Click on the link or Scan the QR code to read the Pharma Sources Insight (April 2021):

About Pharma Sources Insight

Pharma Sources Insight is a unique source of updated coverages on current events and deep insights into hot areas of the biological pharma industry, from China to the world. It follows up new developments with those among the leading drug-manufacturers in China which further affect the world. 

Now, join PharmaSources.com to get access to news of the Chinese pharmaceutical enterprises and to witness industrial changes through the exclusive perspectives of our expert writers into crucial aspects of the pharmaceutical field, all under PharmaSources.com and CPhI China.